Physician profile
Ellen M Early
NPI 1912995960
$4,428.49
in general payments reported to CMS, 2019-2025
44 companies · $449 in 2025
The $449 reported for 2025 was less than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $405 · 2020: $374 · 2021: $520 · 2022: $710 · 2023: $968 · 2024: $1,003 · 2025: $449.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,420.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,420.07 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $498.67 | 2020-2025 | |
| Novartis Pharmaceuticals Corporation | $423.98 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $320.80 | 2019-2025 | Keytruda, Lynparza, Recarbrio |
| Mirati Therapeutics, INC. | $271.83 | 2023-2024 | Krazati |
| E.R. Squibb & Sons, L.L.C. | $266.89 | 2019-2024 | Opdivo |
| Janssen Biotech, INC. | $249.67 | 2019-2024 | Tecvayli, Darzalex, Talvey |
| Daiichi Sankyo INC. | $247.12 | 2022-2025 | Enhertu |
| Amgen INC. | $241.50 | 2019-2023 | Blincyto |
| Astrazeneca Pharmaceuticals LP | $205.77 | 2021-2025 | Lynparza, Calquence, Enhertu |
| Incyte Corporation | $150.38 | 2019-2023 | Jakafi |
| Eisai INC. | $130.11 | 2021-2022 | |
| Glaxosmithkline, LLC. | $123.30 | 2022-2024 | Jemperli, Zejula |
| Karyopharm Therapeutics INC. | $111.44 | 2022-2023 | Xpovio |
| Genzyme Corporation | $99.72 | 2021-2025 | |
| Celgene Corporation | $90.66 | 2020-2024 | Reblozyl |
Show all 44 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ellen Early listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.